The United States (US) Advisory Committee on Immunization Practices recommends a 2-dose series of HAV or a 3-dose series of HAV+HBV vaccinations for all patients with CLD, including those with HBV, HCV, cirrhosis, NAFLD, alcoholic liver disease, autoimmune hepatitis, or alanine aminotransferase or aspartate aminotransferase level >2 the upper limit of normal.20 Similarly, in the United Kingdom (UK), patients with various chronic liver conditions are recommended to receive HAV vaccination.21 The gene discussed is GPT; the disease is autoimmune hepatitis.